Omeros Corporation (OMER) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Negative equity ⢠Zero revenue ⢠Financing-dependent OMER faces severe solvency and liquidity stressâno revenue, sustained heavy losses and negative equity, high debt and a plunging current ratio, with operations kept afloat mainly by external financing while tangible assets offer limited recovery value.
Price Behavior
Key Price Behavior Insights: ⢠Below last-month SMA ⢠Support cluster ⢠Resistance cap Support Level: $11.40â$11.60 Resistance Level: $12.00â$12.05 Price has drifted below its last month SMA (~$11.65) to $11.19 with RSI ~44, holding short-term support around $11.40â$11.60 but capped by resistance near $12.00â$12.05, indicating a shallow short-term downtrend and muted momentum with downside risk on volume.
Sentiment & News
Key News Insights: ⢠Primate study ⢠Valuation comparison ⢠Investor scrutiny Omeros reported positive nonhuman primate efficacy/safety data for OncotoXâAML while analysts and investors continue to evaluate the company against peers on valuation, ownership, and risk metrics.
AI Summary
OMER has moved from a binary clinical bet to a conditional commercial/licensing recovery tradeâits nearâterm investment thesis now hinges on timely receipt of Novo Nordisk deal proceeds and early narsoplimab (YARTEMLEA) launch orders/pricing to extend runway and avoid dilutive financings. Monitor Novo closing/upfront timing, initial hospital order volume/NTAP progress, and upcoming debt covenants as immediate catalysts that will validate or destroy the recovery case.
Description
Omeros Corporation is a commercial-stage biopharmaceutical company that develops small-molecule and protein therapeutics for inflammation, complement-mediated disorders, immune-related cancers, and addictive or compulsive disorders. Its pipeline spans late-stage assetsâmost notably a MASP-2 antibody that has completed a pivotal study for HSCTâTMA and is in Phase III for IgA nephropathy and aHUSâthrough earlier clinical programs and preclinical work on MASP-targeted small molecules, longer-acting antibodies, GPCR targets, and cell therapies. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | OMER | Omeros Corporation | Omeros Corporation is a high-conviction hot idea driven by the transformative FDA approval of YARTEMLEAÂŽ (first approved treatment for TA-TMA), an 80%+ stock surge to 12-month highs, strategic capital infusion via license deal with Novo Nordisk, and strong near-term commercial launch prospects starting 2026. | Closed | -7.1% |